The terms risk factor, prognostic factor and predictive factor are often imprecisely used. We de®ned a prognostic factor as a patient characteristic that identi®es subgroups of untreated patients having different outcomes, and a factor predictive of treatment effect as a patient characteristic that identi®es subgroups of treated patients having different (as a consequence of treatment) outcomes. To illustrate this, theoretical graphical examples were constructed and data from the literature on prostate cancer were used to substantiate the theoretical examples. In most situations, but not necessarily always, a prognostic factor is also predictive of the effect of speci®c treatments. Whether a prognostic factor is also predictive of treatment effect or not can only be assessed in a valid comparative setting such as in a randomized trial. A factor that is predictive for treatment effect may not be predictive for another treatment. Prostate Cancer and Prostatic Diseases (2000) 3, 265±268.
Introduction
The terms risk factor, prognostic factor and predictive factor are often imprecisely used. The outcome of a disease depends on, and can be foreseen by, a multitude of factors. These factors are related to the patient, the disease and the treatment given. Such factors can often be identi®ed in retrospect when the ®nal outcome is known. However, in clinical practice the patient and the treating doctor are more interested in trying to depict the possible outcome prospectively and to attempt to foresee how different interventions could change the course of the disease.
The term risk factor is most often associated with the etiology and development of a disease, for instance, cigarette smoking as a risk factor for developing urothelial cancer. The terms prognostic and predictive factors are more used in the context of foreseeing a possible outcome for a patient with a speci®c disease. These factors are various characteristics related to the patient, for instance age, or to the disease, for instance, tumor grade. Such factors are associated with the disease and its course strongly enough to foresee the outcome, but do not necessarily cause the outcome. In malignant diseases, tumor grade and tumor stage according the TNM classi®cation are widely used and appreciated as factors that are able to foresee the disease course. What is seldom discussed, is that the outcome foreseen by, for instance, tumor grade, is most often a combination of the impact of the disease on the patient and the modifying effect of the treatment. Thus, to distinguish the difference in in¯uence of the disease and the treatment one may de®ne a prognostic factor as one that foresees the outcome of the disease by itself, and a treatment predictive factor as one that foresees the modifying effect of a treatment on the disease (Table 1) .
We have described previously the difference between factors giving prognostic information and factors predicting the treatment effect in arithmetical terms. 1 The present paper aims to further elucidate the difference between prognostication of a disease and prediction of treatment outcome relative to factors often used in this context.
Results
In Figures 1 ± 3 , we give theoretical graphical examples. The proportion of surviving patients is related to followup time. In the ®rst graph in each pair (1a, 2a, 3a) no treatment has been given and the second (1b, 2b, 3b) represents treated groups. The two lines depict the outcome in two subgroups of the investigated factor, for instance, high or low age, high or low tumor grade, etc.
In Figure 1 , the factor is prognostic because a split into groups 1 and 2 gives a different outcome in the subcategories without treatment. The factor is also predicting the outcome of the treatment since subcategory 1 has a better outcome after treatment than after no treatment. However, no treatment effect is seen in subcategory 2 of the factor. The factor in this situation is both prognostic and predicting a treatment effect.
In Figure 2 , the subcategories of the factor give prognostic information without treatment. Since the outcome is unchanged after treatment, the subcategories do not predict any effect of the treatment. In this case the factor is prognostic but does not predict any treatment effect.
In Figure 3 , subcategorization is not prognostic since there is no difference in outcome between the subcategories without treatment. With treatment, the outcome for patients in subcategory 1 improves. The factor is therefore not prognostic, but predictive of treatment effect.
Discussion
The strict implication of the de®nitions of prognostic and treatment effect predictive factors used in this paper is that the prognostic value of a factor can only be related to the natural course of the disease, that is, without treatment. In reality, there are few conditions that are left without any treatment. Thus, pure prognostic information is dif®cult to obtain for many diseases.
If a factor is predictive of outcome after treatment, that is, if treatment changes the outcome in one subgroup, or more in one subgroup than in another, it is best tested in randomized trials (Table 2 ). In a strict sense, the ability of a factor to predict treatment outcome must be evaluated for each speci®c treatment. The process of evaluating if a factor is predictive of treatment effect is however, for most diseases, rather cumbersome and most often such an ability of a factor is more or less assumed. Since the distinction between prognostic and treatment effect predictive properties of a factor is seldom made, the notion that a factor is prognostic or predictive of treatment effect is usually based on the ®nding of a different outcome for 
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subgroups of the factor in single treatment, noncomparable, patient series. In most situations the varying outcome in subgroups probably re¯ects a mixture of prognostic and treatment effect predictive information. For prostate cancer the best estimate of the natural course we can get is from contemporary series on patients on deferred treatment (also called watchful waiting). In these series a large proportion of the patients remain without treatment for long periods of time or even until death caused by another disease. 2, 3 The treatment given if necessary is most often hormonal treatment, ie not curative.
In one observation patients with well or moderately differentiated prostate cancer had the same 10-y diseasespeci®c survival and patients with poorly differentiated tumors fared much worse when managed by watchful waiting. 4 In another observation the 10-y disease-speci®c survival for patients with poorly differentiated prostate cancer was almost twice as high after radical prostatectomy as in the previous observation. 5 The differences in outcome for patients with well or moderately differentiated tumors were small. These two observations indicate grade is both prognostic and treatment effect predictive for radical prostatectomy (Figure 1) .
On the other hand, in the O È rebro series on watchful waiting, patients with well-differentiated tumors fared better than patients with moderately differentiated tumors. 3 Moreover in the randomized VACURG study of patients with well or moderately differentiated tumors the overall survival was similar 20 y after treatment with radical prostatectomy or watchful waiting. 6 If these two observations represent the truth, tumor grade is prognostic but not predictive for treatment with radical prostatectomy versus watchful waiting (Figure 2) .
Moreover, in one observation the outcome of patients with diploid versus tetraploid clinically localized prostate cancers was not different when managed by watchful waiting. 7 However, patients with diploid prostate cancers with regional lymph node metastases managed by radical prostatectomy fared better than similar patients with tetraploid and aneuploid tumors. 8 If these two observations re¯ect the true situation, ploidy is not prognostic for patients with localized tumors but predictive for the treatment effect when patients with N /D1 prostate cancer are managed by radical prostatectomy (Figure 3) .
A parallel to the problem of de®ning prognostic and treatment effect predictive properties of a factor is the evaluation of a diagnostic test. The value of a diagnostic test is often not only its ability to detect a disease but a combination of this and the ef®cacy of a given treatment. In a screening situation nothing is gained by identifying more individuals with an abnormal test, indicating a disease, if we do not have a treatment that is effective. Likewise, if the treatment is not more effective in patients detected earlier by screening than in those detected in regular clinical practice nothing is gained by the test.
The examples above can easily be challenged for many reasons and in reality we do not have any data that can provide us with a reasonable differentiation between prognostic and treatment effect predictive value of various factors in the prostate cancer ®eld. This is mostly a re¯ection of a rather poor scienti®c situation. To con®rm that a factor gives both prognostic and treatment predictive information one needs a randomized study strati®ed for the factor in question, that is, at least four different groups. For instance, if a study randomizes between no initial treatment and active curative treatment for early prostate cancer, and the study is strati®ed for low and high grade, grade would be prognostic if there is a difference in outcome between the low and high-grade group in the patients with no initial treatment. The factor would predict the treatment effect if treatment changes the outcome in only one of the two subgroups or if the change was different in the subgroups (Table 2 ). To our knowledge no such study has been published but both the PIVOT trial 9 and the SPCG-4 trial 10 randomizing patients to deferred treatment against radical prostatectomy, will be able to give such information.
Conclusions
A prognostic factor is most often, but not necessarily, also predictive of the effect of speci®c treatments.
Whether a prognostic factor is also predictive of treatment effect or not can only be assessed in a valid Prognostic and treatment-predictive factors J Adolfsson & G Steineck comparative setting. The randomized trial is the golden standard to obtain such a setting. A factor that is predictive for treatment effect may not be predictive for another treatment. Also, if a factor predicts (for a speci®c treatment) the effect on one outcome, it may or may not predict the effect for another outcome.
